retatrutide triple agonist clinical trial produces up to 30.3% weight loss in Phase 3 Retatrutide Dosing Guide: 1-12 mg

Today Ely Lilly (LLY) announced the positive results on a phase 2 diabetes drug of theirs ( LY3298176 ) via a publication in The Lancet, a presentation at the annual meeting of the European Association for the Study of Diabetes (EASD) and the press release below: Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes The press release created a few headlines: Bloomberg: Diabetes Drug's Results Push Lilly to Look at Obesity Too Reuters: Lilly's diabetes drug data impresses, hurts rival Novo's shares The share price of Eli Lilly went up by 4% in an otherwise sour market and that of Danish rival Novo Nordisk (NOVO-B.CO) plummeted some 7-8%

Daily-use products benefit from conservative concentrations that enable consistent long-term application without irritation

You cant yet join a peer support group with the confidence that comes from knowing its an evidence-based bipolar treatment

The sulfur-containing amino acids: An overview

Store in a cool, dry place away from moisture and sunlight